Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal
cell carcinoma (mRCC). Specifically, patients received either targeted therapy or …

Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …

Opinion statement Treatment of metastatic clear cell renal cancer (mccRCC) has seen
substantial progress over the last 20 years, with many regulatory approvals since 2006 …

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly
evolving with improved knowledge of the biology of disease leading to the incorporation of a …

Simple Summary Renal cancer is within the top 10 most common malignancies worldwide,
of which clear cell histology represents the most common subtype in this cancer. Within the …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

First-line treatment for metastatic clear-cell renal cell carcinoma patients with intermediate
and poor-risk features consists of a combination of immune checkpoint inhibitors (eg …

Simple Summary First-line treatment options for metastatic clear cell renal cell carcinoma
have significantly increased. The current recommended therapeutic strategy is based on a …

Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of
metastatic renal cell carcinoma, new and clinically relevant questions have emerged that …

Abstract Purpose of Review Four immuno-oncology (IO)-based combinations have
demonstrated overall survival benefit as frontline treatment of metastatic clear cell renal cell …